arrow
K

Katharina Hansel

University of Perugia
H指数:28
被引数:2,542

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Contact Allergy to Textile Dye Mix in Italy: A SIDAPA Multicentre Observational Study

意大利纺织染料混合物接触性过敏:一项SIDAPA多中心观察性研究

2026-10-230
OA
Treatment Outcomes of Lebrikizumab after Switching from Dupilumab in Moderate-to-Severe Atopic Dermatitis involving the Head and Neck Area

从度普利单抗转换至lebrikizumab治疗涉及头颈区域的轻中度特应性皮炎的疗效结局

2026-07-220
OAAI
Dupilumab for Prurigo Nodularis: Real-World Outcomes Up to 104 Weeks from the DUPItaPN Study

度普利尤单抗治疗结节性痒疹:DUPItaPN研究104周真实世界结局

2026-04-150
OA
Real-Life Workup of Chronic Hand Eczema Using a Dedicated Case Report Form: A SIDAPA Multicentre Study

使用专用病例报告表对慢性手部湿疹进行真实世界诊疗评估:一项SIDAPA多中心研究

2026-02-150
OAAI
Psoriasis and seronegative spondyloarthropathy in patients with atopic dermatitis treated with dupilumab or tralokinumab: a multicentre observational study

特应性皮炎患者接受度普利尤单抗或特拉利尤单抗治疗时的银屑病和血清阴性脊柱关节病:一项多中心观察性研究

2026-02-011
PRE
Letter: Optimizing Dupilumab Dosing in Atopic Dermatitis: Real-World Evidence

信函:优化特应性皮炎中度普利单抗的剂量:真实世界证据

2025-11-070
PRE
Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study

有效性、安全性及与健康相关的生活质量:接受Lebrikizumab治疗的轻中度特应性皮炎的16周全国性回顾性队列研究

2025-10-100
OA
Therapeutic outcomes across Janus kinase inhibitors in prurigo nodularis

结节性痒疹中Janus kinase抑制剂的疗效比较

2025-09-010
PRE
Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study

特应性皮炎患者中结膜炎的发病率、危险因素和管理:一项多中心、观察性、回顾性研究的结果(Dupilumab或Tralokinumab治疗组)

2025-08-200
OAAI
Clinical course of atopic dermatitis after dupilumab discontinuation: a multicentre real-world study

特应性皮炎在度普利尤单抗停药后的临床病程:一项多中心真实世界研究

2025-08-010
PRE
Effectiveness and Safety of Adalimumab Biosimilars in Pediatric Psoriasis: A Multi-Center International Experience

阿达木单抗生物类似药在儿童银屑病中的有效性与安全性:一项多中心国际经验

2025-06-280
OA
Letter: Effectiveness and Safety of Tralokinumab for the Elderly with Atopic Dermatitis in a Real-World Setting—IL AD

信函:曲扎基珠单抗在真实世界环境中用于老年特应性皮炎患者的有效性与安全性—IL AD

2025-06-050
PRE
Enhancing Skin Cancer Prevention and Awareness in the Italian Population: Insights from the Save Your Skin Screening Campaign

提升意大利人群皮肤癌预防与意识:来自“拯救你的皮肤”筛查运动的经验与启示

2025-04-110
PRE
Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes

Tralokinumab在特应性皮炎表型中的有效性

2025-03-180
OAAI
Efficacy and drug survival of tralokinumab in patients with severe atopic dermatitis: an 18-month multicentre study
2025-02-030
PRE
Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian Study
2025-01-230
OAAI